Healthcare, life sciences and pharmaceuticals


We hold a strong position in this sector because we respond to the need for legal support in new areas of scientific knowledge and of biomedical technologies, one of the biggest challenges in recent decades in terms of innovation and development.

We provide legal assistance to Portuguese and international companies that operate in healthcare, life sciences and pharmaceuticals, particularly in the regulatory, business and competition areas.

We have the know-how our clients need on developments in Portuguese and international legislation, and on legislative policies in the area of regulation, and implementation and enforcement of strategies. We do not only advise on traditional pharmaceutical industry issues and research. Our team is also skilled in new issues in the area of biomedical research. These include nanotechnology, diagnosis, genomics, medical devices, biobanks, bioinformatics, genetic testing, pharmacogenetics, new drugs and clinical trials. We also assist clients on new medical technologies such as medically assisted procreation and stem cells.

Another important aspect of our work is helping our clients protect their biotechnological inventions by advising them on development and transfer of technology, and on patents. We help our clients on data protection issues for doctors and in respect of genetics and biometrics.

We advise companies that work with pharmaceutical products, biotechnology and medical devices. We also advise companies in pharmaceutical distribution, and even regulatory authorities, academic institutions and other organisations involved in medical care.

Other Awards
2024 LMG Life Sciences Awards 2024 Non-IP Litigation Rising Star
Chambers Europe
2022 Life Sciences Recommended Tier 1
2021 Life Sciences Recommended Tier 1

"The team is very dedicated and swiftly reply to our queries. They are interested, proactive and enthusiastic - they identify a problem and simultaneously present a strategy to overcome it."

2019 Life Sciences Recommended Tier 1

"Clients are impressed by the team's very broad, strategic vision of life science issues and also the department's "great support" and underline its capabilities in regulatory matters."

Please note, your browser is out of date.
For a good browsing experience we recommend using the latest version of Chrome, Firefox, Safari, Opera or Internet Explorer.